LYON, France--(BUSINESS WIRE)--ERYTECH Pharma, a late stage biopharmaceuticals company focused on orphan oncology and rare diseases, announces that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) adopted a positive opinion to grant Orphan Drug Designation (ODD) to its investigational product ENHOXY® for sickle cell disease. ENHOXY®, human erythrocytes encapsulating inositol hexaphosphate, enhances the oxygenation properties of red blood cells by reducing...  Full Article  @ BusinessWire - 1 year ago